ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0559

Role of Adipose Tissue-Derived Mesenchymal Stem Cells in CKD: A Phase 1 Study Assessing Safety and Clinical Feasibility

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Cai-Mei, Zheng, Taipei Medical University College of Medicine, Taipei, Taiwan

Chronic kidney disease (CKD) is a most common progressive disorder associated with high mortality and huge socio-economic burden globally. We hypothesize that allogeneic adipose tissue mesenchymal stromal cells (hASCs) are renotropic and may retard CKD progression through anti-apoptotic, anti-fibrotic, and anti-inflammatory effects. In this study, we will assess the safety and tolerability of a hASCs infusion in CKD patients with various underlying etiologies.


We performed a single-arm phase I clinical trial with a 6-month follow-up. This study enrolled 12 eligible CKD patients with an estimated glomerular filtration rate (eGFR) of 15-44 mL/min/1.73m2 (mL/min). Patients were allocated to receive low, moderate, or high dose of allogeneic cultured hASCs infusion. We investigated the safety issues and kidney function during the follow-up visits.


There was no patient lost to follow-up. We observed two treatment related adverse events (AE) in high dose group. One subject experienced grade 1 slow speech immediately after hASCs infusion, which was resolved on the next day and completely normal afterwards. The AE was considered possibly related to study treatment and met dose-limiting toxicity (DLT). Another subject experienced grade 1 bradyphrenia after the infusion, and the situation was resolved during the following 9 days, however, this AE was not considered as DLT. One SAE was reported in moderate dose group, who was hospitalized for persistent heavy proteinuria, and later proved as diabetic nephropathy stage 4 by renal biopsy. No significant reduction in eGFR was noted among all treated patients, and specifically an improvement in eGFR was noted among those with baseline eGFR>30mL/min. No significant reduction in proteinuria was noted.


This trial demonstrated the safety and tolerability of allogenic hASCs infusion in stages 3b and 4 CKD patients. Patients with reserved renal function (e.g. eGFR>30mL/min) could be more beneficial from hASCs compared to those without. hASCs efficacy and dosing interval in various CKD stages should be investigated in future randomized placebo-controlled trial among various CKD population.